In April, biopharmaceutical company Petrovax that is among the TOP5 immunobiological manufacturers in Russia was issued approvals to boost production of medicinal products due to prompt decisions made by the Russian Ministry of Industry and Trade and the Ministry of Health (MoH).
On the back of the COVID-19 pandemic, Petrovax is significantly ramping up production of its branded product Polyoxidonium® for the treatment and prevention of acute respiratory viral infections (ARVI).
Amid the global COVID-19 pandemic, Polyoxidonium® (INN: azoximer bromide) production is especially important for the company. The product has been included into the Temporary Guidelines for ARVI treatment during COVID-19 epidemic 1. In April, Petrovax was issued a MoH’s approval for international multicenter clinical trials to study Polyoxidonium® efficacy and safety in hospitalized COVID-19 patients. The international portion of the trials is to start soon.